QNTMHealthcare · BiotechnologyThe 1 Wall Street analysts covering Quantum BioPharma Ltd. hold a median 12-month price target of $13 — +268.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Quantum BioPharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (87): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (9): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on QNTM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +268.5% from it.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QNTM appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 79% of US stocks
Cheaper than 3% of US stocks
Cheaper than 71% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 2% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Quantum BioPharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Quantum BioPharma issued a corporate update via GlobeNewsWire. The release is intended for distribution in Canada only and is not intended for distribution in the United States.
Why it matters — A QNTM watcher would care because the update provides official corporate information, though its distribution is limited to Canada.
Quantum BioPharma reported its second-quarter 2026 financial and operational results, ended June 30, 2026, saying it strengthened its equity and liquidity. The FDA approved Lucid-MS for a pivotal Phase 2 clinical trial.
Why it matters — QNTM watchers would care because FDA approval to advance Lucid-MS into a pivotal Phase 2 trial is a key clinical milestone for the company's pipeline, alongside its reported improvements in equity and liquidity.
Quantum BioPharma announced that the U.S. FDA has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), a patented first-in-class neuroprotective therapy targeting demyelination. This clearance enables the company to begin a randomized, double-blind, placebo-controlled Phase 2 clinical trial in progressive multiple sclerosis.
Why it matters — FDA clearance to advance Lucid-MS into Phase 2 represents a significant regulatory milestone for Quantum BioPharma's lead multiple sclerosis program, moving its novel disease-modifying candidate closer to addressing a progressive MS market with substantial unmet medical need.
Quantum BioPharma Ltd. announced the closing of a debt settlement, according to a press release intended for distribution in Canada only.
Why it matters — Closing a debt settlement can improve Quantum BioPharma's balance sheet by resolving outstanding liabilities, which shareholders may view as a step toward financial stability.
The 1 Wall Street analysts covering Quantum BioPharma Ltd. have a median 12-month price target of $13, with estimates ranging from $13 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Quantum BioPharma Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quantum BioPharma Ltd. 43 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Quantum BioPharma Ltd. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (87 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +268.5% from the last close, and Ticker Nerd's factor model ranks Quantum BioPharma Ltd. 43 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Quantum BioPharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QNTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $13 over the next 12 months.
Quantum BioPharma Ltd. returned -80.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company focused on researching and developing a portfolio of innovative assets and biotech solutions targeting neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders.
The most recent item we track (GlobeNewsWire, 21 Aug 2026): "Quantum Biopharma Provides Corporate Update". Quantum BioPharma issued a corporate update via GlobeNewsWire. The release is intended for distribution in Canada only and is not intended for distribution in the United States.
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company focused on researching and developing a portfolio of innovative assets and biotech solutions targeting neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders. Operating through its Biopharmaceutical Innovation and Strategic Investments segments, the company advances drug candidates at various development stages, including its lead compound Lucid-MS, a patented new chemical entity designed to prevent and reverse myelin degradation in multiple sclerosis, currently advancing toward Phase 2 clinical trials. Additional pipeline assets include FSD-PEA for inflammatory diseases like mast cell activation syndrome, Lucid-PSYCH for major depressive disorder, and unbuzzd, a proprietary formulation of vitamins and minerals to support liver and brain function in relieving alcohol consumption effects. Through its subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma drives core R&D efforts, while FSD Strategic Investments Inc. manages a portfolio of secured loans on residential and commercial properties. The company also holds an equity stake and royalties in Unbuzzd Wellness Inc. for the over-the-counter unbuzzd product, alongside a digital asset portfolio as part of its treasury strategy. Headquartered in Toronto, Quantum BioPharma plays a role in addressing unmet needs in central nervous system therapeutics and related health solutions.
CEO Mr. Zeeshan Saeed · 17 employees · Canada · https://www.quantumbiopharma.com